Advocates Get OPEN Act Back In Latest Cures Draft Ahead Of Thursday Markup

House lawmakers, facing pressure from more than 150 patient and rare disease advocacy organizations, put back into their latest Cures draft a measure to grant an additional six months of exclusivity for approved drugs that receive a new indication for a rare disease or condition, after having dropped the language from the second draft of the bill unveiled in late-April. The Orphan Product Extensions Now (OPEN) Act was the only exclusivity provision that made its way back into the updated...